Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GRM8 | O00222 | 1/20 | 0.45 |
| ▸ | GRM6 | O15303 | 1/20 | 0.45 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 2/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13884501 | 1.00 | ALDH1A1 (0.54) | ALDH1A1L3MBTL1GAACYP1A2TSHR | |
| SCHEMBL5496015 | 0.87 | KMT2A (0.55) | ALDH1A1L3MBTL1GAATDP1AKR1C3 | |
| SCHEMBL12814779 | 0.84 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1AKR1C3AKR1C2 | |
| SCHEMBL14450727 | 0.84 | L3MBTL1 (0.60) | ALDH1A1L3MBTL1GAACYP1A2TSHR | |
| SCHEMBL6474872 | 0.84 | KMT2A (0.56) | ALDH1A1GAATDP1KMT2AMEN1 | |
| SCHEMBL8646829 | 0.83 | ALDH1A1 (0.46) | ALDH1A1CYP1A2TSHRTDP1AKR1C3 | |
| SCHEMBL11137284 | 0.83 | L3MBTL1 (0.71) | ALDH1A1L3MBTL1GAACYP1A2TSHR | |
| SCHEMBL31718130 | 0.83 | AKR1C3 (0.62) | ALDH1A1TDP1AKR1C3AKR1C2KMT2A | |
| SCHEMBL135650 | 0.83 | AKR1C3 (0.62) | ALDH1A1TDP1AKR1C3AKR1C2KMT2A | |
| SCHEMBL27503218 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRTDP1AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114397397-A | Detection reagent for lipoprotein-associated phospholipase A2, preparation method and determination method | 深圳市三励方科技有限公司 | 2022-04-26 | — | — | CN | disclosed |
| EP-2059565-B1 | MODIFIED COLORANTS WITH ALIPHATIC POLY-ACID GROUPS | CABOT CORP (US) | 2014-06-11 | — | — | EP | disclosed |
| US-8021471-B2 | Modified colorants with aliphatic poly-acid groups | CABOT CORPORATION (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| EP-2059565-A2 | MODIFIED COLORANTS WITH ALIPHATIC POLY-ACID GROUPS | Cabot Corporation (US) | 2009-05-20 | — | — | EP | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-20080083347-A1 | Readily dispersible in liquid vehicles; stability; ink jet pigments; quality optical density on plain paper | CABOT CORPORATION | 2008-04-10 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20020077491-A1 | Methods for forming combinatorial libraries combining amide bond formation with epoxide opening | NEOGENESIS PHARMACEUTICALS, INC. | 2002-06-20 | — | — | US | disclosed |
| WO-2002020436-A2 | METHODS FOR FORMING COMBINATORIAL LIBRARIES COMBINING AMIDE BOND FORMATION WITH EPOXIDE OPENING | NEOGENESIS PHARMACEUTICALS, INC. (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-0891325-B1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | SEARLE & CO (US) | 2002-02-06 | — | — | EP | disclosed |
| EP-1157985-A1 | Para- substituted phenylene derivatives and their use as integrin antagonists | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| US-6251944-B1 | (VITRONECTIN RECEPTOR) INTEGRIN ANTAGONIST, USEFUL FOR TREATING ANGIOGENESIS, TUMOR GROWTH, TUMOR METASTASIS, OSTEOPOROSIS AND HUMORAL HYPERCALCEMIA OF MALIGNANCY | G. D. SEARLE & COMPANY | 2001-06-26 | — | — | US | disclosed |
| US-5952381-A | SELECTIVELY INHIBITING OR ANTAGONIZING THE INTEGRINS; ANTITUMOR AGENTS, ANTIARTHRITIC AGENTS, VIRICIDES, MICROBIOCIDES; TREATING OSTEOPOROSIS, SKIN DISORDERS | G. D. SEARLE & CO. (US) | 1999-09-14 | — | — | US | disclosed |
| WO-1999035129-A1 | SUCCINIMIDE DERIVATIVES WHICH INHIBIT RETINOIC ACID METABOLISM | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 1999-07-15 | — | — | WO | disclosed |
| EP-0891325-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1999-01-20 | — | — | EP | disclosed |
| WO-1997036859-A1 | PARA-SUBSTITUTED PHENYLPROPANOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020077491-A1 | Methods for forming combinatorial libraries combining amide bond formation with epoxide opening | EPHX2, COASY, EPHX1 | ALDH1A1 221/4885L3MBTL1 3831/4885GAA 2745/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | ALDH1A1 2335/4885L3MBTL1 1626/4885GAA 3491/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | ALDH1A1 1061/4885L3MBTL1 1354/4885GAA 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.